key: cord-1001730-n5n1u8ag
authors: Lektemur Alpan, A.; Torumtay Cin, G.; Özmen, Ö.; Doğan, M. F.; Şahin, Y.
title: Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats
date: 2022-05-16
journal: J Evol Biochem Physiol
DOI: 10.1134/s0022093022020119
sha: 5084b39981ced00e386f7a7e6f2486a5ddb001de
doc_id: 1001730
cord_uid: n5n1u8ag

Introduction: Favipiravir and Vitamin C (Vit C) were used together in the treatment of the COVID-19 pandemic. However, the effects of favipiravir on the periodontium are still unknown. Therefore, the aim of this study was to investigate the effects of Favipiravir and Vit C treatment on alveolar bone metabolism. Experimental: Fifty healthy adult male Sprague-Dawley rats (2–3 months old) were randomly divided into five equal groups (n = 10): Control, Favi 20, Favi 100, Favi 20+Vit C, Favi 100+Vit C. Favipiravir (20 mg/kg and 100 mg/kg, i.m.) and Vit C (150 mg/kg/day, oral) were administered to the rats for 14 days. Alveolar bone loss (ABL) and histopathological changes were examined using a light microscope. Immunohistochemistry was used to determine levels of receptor activator of nuclear factor kappa-B ligand (RANKL), caspase-3, bone morphogenic protein 2 (BMP-2) and alkaline phosphatase (ALP) in the bone tissues. Results: Favipiravir increased the levels of RANKL and caspase-3 expression but decreased BMP-2 and ALP levels in a dose-dependent manner. Favi 20+Vit C and Favi 100 +Vit C groups showed decreased RANKL and caspase-3 levels in addition to increased BMP-2 and ALP levels. Conclusion: Favipiravir can cause histopathological damage to the periodontium, but administration of favipiravir combined with Vit C can provide a protective effect against this damage.

In December 2019, an epidemic started with symptoms like pneumonia in Wuhan, China, and, expanded to the world and was named coro navirus disease 19 (COVID 19) by the World Health Organization (WHO) [1, 2] . Favipiravir which is a broad spectrum antiviral drug, is a pyrazine carboxamide derivative and is used for treatment of influenza in Japan [3] . Favipiravir is also used as a potential treatment agent for COVID 19 but clinical studies are still in prog ress [4] . Active favipiravir competes with purine nucleosides and interferes with viral replication by incorporation into virus RNA, thereby poten tially inhibiting the RNA dependent RNA poly merase (RdRp) of RNA viruses [4] . As a result of animal studies in which dose toxicity was investi gated after oral administration of favipiravir, effects such as an increase in liver enzymes (aspartate aminotransferase-AST, alkaline phosphatase-ALP, alanine aminotransferase-ALT, total bilirubin), hepatocyte vacuolization and a decrease in red blood cell (RBC) produc tion were observed [5] . It is also known that favi piravir is teratogenic; therefore, the administration of favipiravir should be avoided in pregnant women [6] . It was reported by clinical and laboratory studies that COVID 19 treatment with favipiravir had fewer adverse effects com pared to other antiviral drugs [7] .

Vitamin C (Vit C) is an essential antioxidant that participates in the improvement, mainte nance, and function of various cell types in the body. Such pharmacological properties of Vit C as antiviral, anti inflammatory, antioxidant, and immunomodulating effects have also been demonstrated [8] . A recent study demonstrated that intravenous administration of high dose of Vit C for COVID 19 management generates positive results without adverse effects [9] . Both favipiravir and Vit C are among the treatment options for COVID 19 and related studies have been carried out strenuously in many countries [10] .

While increasing evidence indicates that there may be an association between COVID 19 infection and periodontitis, maintenance of peri odontal health could become an essential factor in preventing its complications, but the effects of favipiravir on alveolar bone are not known. As a result, the purpose of this study was to examine the effects of favipiravir at various doses with or without Vit C supplementation on rat alveolar bone metabolism using such parameters as receptor activator of nuclear factor kappa B ligand (RANKL), caspase 3, alkaline phospha tase (ALP), and bone morphogenic protein 2 (BMP 2).

The animal experiments were approved by the Animal Experimentation Ethics Committee in Pamukkale University (PAUHDEK 2021/23). The study was carried out following the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies [11] . Fifty healthy adult male Sprague Dawley rats (2-3months old) were kept in cages at 22 ± 1°C in 12 hour light/dark cycles. The rats received stan dard pellet shaped rodent food and water ad libi tum until euthanization. Animals were weighed weekly. Fifty rats were randomly distributed into 5 equal groups (n=10):

1. [12] . At the end of 14 days, all rats were euthanized under anesthesia (80-100 mg/kg of Ketamine; Alfamin, Alfasan IBV and 5-7 mg/kg Xylazine; Alfazin, Alfasan IBV) and samples were collected and stored in 10% formalin at room temperature until analysis.

Mandibula and maxilla samples were collected and fixed in 10% neutral buffered formalin for microscopical evaluation. After 3 days of tissue fixation, the samples were decalcified in 0.1 M ethylenediaminetetraacetic acid solution (EDTA) for 2 weeks, and tissues were routinely processed by an automatic tissue processor (Leica ASP300S, Wetzlar, Germany). Then samples were embed ded in paraffin and 5 μm serial sections were pre pared by a rotary microtome (Leica RM 2155; Leica Microsystems, Wetzlar, Germany) and one serial section was stained with hematoxylin and eosin (HE). Four serial sections were prepared, and two levels of sections were taken from all rats for histopathological and immunohistochemical examinations.

The degree of the alveolar bone loss (ABL) was detected by measuring the distances between the alveolar bone crest (ABC) and cemento enamel junction (CEJ) at six points in all molar teeth localized in both the maxilla and mandible. Lesioned areas were analyzed in each rat using a light microscope (Olympus CX41, Olympus Cor poration, Tokyo, Japan).

Immunohistochemical analysis for RANKL, caspase 3, ALP, and BMP 2 Selected sections were stained to demonstrate the presence of ALP using Anti ALP antibody (ab224335); BMP2-Anti BMP2 antibody (ab14933); RANKL-Anti RANKL antibody (ab216484) and Caspase 3-anti caspase 3 anti body (ab4051) by the streptavidin biotin peroxidase technique, according to the manufacturer's instruc tions. All antibodies were purchased from Abcam, (Cambridge, UK) and used at a 1/100 dilution. An UltraVision Detection System Anti Polyvalenti HRP kit (TP 060 HL) (Thermo Shandon Lim ited, Cheshire, UK) was used for staining with the secondary antibody, and 3,3´ diaminobenzi dine was used as the chromogen. For negative controls, antibody dilution solutions were used instead of primary antibodies. The DAB staining step was completed by checking under a micro scope to prevent background staining, and then washed twice. All tissue examinations were per formed by a specialist pathologist who was blinded to the specimen treatments. All slides were analyzed for immunopositivity by semi quantitative analysis. For this aim, samples were analyzed by assessing five different areas in each rat. Immunohistochemical staining was scored between 0-3. 0 = negative, 1 = low positive, 2 = positive, and 3 = high positive [13, 14] . The scores obtained were analyzed statistically and tabulated. An automated image analysis system (Olympus CX41, Olympus Corporation, Tokyo, Japan) was used to obtain computer assisted histomorpho metric measurements and immunohistochemical scoring to support the data after conventional microscopic examination. The Database Manual CellSens Life Science Imaging Software System (Olympus Corporation) was used for histomor phological and immunohistochemical analysis. IHC score analyses were performed using Image J 1.46r (National Institutes of Health, Bethesda MD).

IHC optical density scores were calculated using the following formula: IHC optical density score = (Percentage contribution of high positive × 4 + Percentage contribution of positive × 3 + percentage contribution of low positive × 2 + percentage contribution of negative × 4) / 100 [15] . 

Statistical analyses were performed using the SPSS 21.0 program. A one way analysis of vari ance post hoc Tukey test was used to reveal signif icant differences between the groups for comparing the alveolar bone loss (ABL). The Kruskal-Wallis comparison test was used to determine differences between groups in the his topathological and immunohistochemical analy ses and p < 0.05 was considered as the level of significance.

No rats were lost during the experimental pro cedure. Intact gingival epithelium and no alveolar bone loss were observed in the Control group. All other groups showed inflammatory reactions like redness and edema in the gingival tissues and also periodontal ligament, degradation of the alveolar process, and low to partial cement destruction (Fig. 1) . ABL was observed in the Favi 100 group compared to the Control group (p > 0.05). The Favi 20, Favi 20+Vit C, and Favi 100+Vit C groups showed the signs of ABL compared to the Control group but the differences were not statis tically significant (Fig. 2 ).

The results of the immunohistochemical examination of BMP 2, one of the precursor markers of bone formation, the Favi 20, and Favi 100 groups revealed decreased immunore activity compared to other groups (p < 0.05). The BMP 2 staining in the Vit C applied favipiravir groups approached the levels in the Control group (p > 0.05) (Fig. 3) . According to IHC scores, all favipiravir applied groups revealed decreased BMP 2 activity compared to The Control group (p < 0.05) ( Table 1) . When the ALP, another important bone formation marker, was examined, decreased immunoactivity was observed in all groups compared to the Control group. Administration of Vit C increased ALP immunoreactivity, with the increase being espe cially pronounced in the Favi 100+Vit C group (Fig. 4) . ALP immunoreactivity was statistically decreased in the Favi 100 group compared to the Control group (Table 1) . Caspase 3 plays an important role in the intrinsic and extrinsic path ways of programmed cell death. In this recent study, caspase 3 imunoreactivity was signifi cantly increased in the Favi 20, Favi 100, and Favi 100+Vit C groups compared to the Control group (p < 0.05) whereas the Favi 20+Vit C group showed similar immunostaining (p > 0.05) (Fig. 3, Table 1 ).

Immunohistochemical examination revealed that both doses of favipiravir increased RANKL immunoreactivity compared to the Control group (p < 0.05) (Fig. 3, Table 1 ) in a dose dependent manner. The Favi 100 group showed the highest RANKL levels among the groups. Vit C adminis tration decreased RANKL immunoreactivity, increased by favipiravir, in the Favi 20+Vit C and Favi 100+Vit C groups. Although similar RANKL immunoreactivity wase observed in the alveolar bone border, the affected area was mainly in the periodontal ligament with RANKL immunopos itive cells being mainly localized in the periodon tal ligament (Fig. 4) . Most of the RANKL immunopositive cells were osteoclasts, osteo blasts, and fibroblasts. 

In the present study, the effects of favipiravir and favipiravir combined with Vit C, a treatment option for the current pandemic, on the peri odontium were investigated in rats by histological and immunohistochemical methods. To the best of our knowledge, this is the first study evaluating the effects of favipiravir, an antiviral agent used in COVID 19 treatment, on the periodontium. Our results showed that high doses of favipiravir caused an increase in caspase 3 and RANKL lev els and a reduction in ALP and BMP 2 levels. Administration of Vit C ameliorated favipiravir induced apoptosis as measured by caspase 3 and RANKL in osteoblasts, with an increase in ALP and BMP 2 levels being observed.

Broad spectrum antiviral agents are consid ered as the gold standard in the treatment of viral diseases [12] . Favipiravir, used for COVID 19 infection, is a new antiviral agent that prevents viral transcription and replication and acts as an inhibitor of RNA dependent RNA polymerase [16] . It should be used in high doses for effective antiviral activity [17] . However, animal studies have shown that its repeated doses have adverse effects on hematopoietic cells, liver function parameters, and hepatocytes. In addition, dose dependent increases in the serum of the uric acid levels have been detected asymptomatically in humans [18] . Although studies of the effects of antiretroviral treatments and their long term tol erability continue, the impact of these drugs on bone metabolism has become an important issue. Antiretroviral drugs could affect bone cells directly and indirectly through the changes in the RANK/RANKL system, phosphate metabolism, mitochondrial function, and cytokine production [19] . RANKL released by periosteal cells, osteo blasts, and osteocytes, stimulates osteoclast for mation and activity responsible for bone resorption and subsequent binding with RANK. Following the administration of antiretroviral therapy, T lymphocytes become active and trigger bone loss by enhancing the secretion of osteoclas togenic cytokines such as RANKL and TNF [20] . In rats treated with tenofovir, a nucleoside based antiviral drug, an increase in RANKL positive cell counts and a decrease in osteoprotegerin lev els were detected. In that study, tenofovir was also shown to increase the number of osteoclasts in the bone, reduce bone volume and production, and inhibit bone formation by activating MAPK and NF kB signaling pathways involved in triggering osteoclastic differentiation [21] . It has been deter mined that a long term treatment regimen with lopinavir, also used for COVID 19 management, causes a reduction in bone mineral density [22] . In the current study, 20 mg/kg and 100 mg/kg of favipiravir for 14 days caused an increase in RANKL levels and induced ABL. A previous study reported that the 150 mg/kg Vit C reduces RANKL induced osteoclastogenesis and associ ated ABL [23] . Vit C diminishes oxidative stress and inflammation via reduction of NF κB pro duction [23] and also decreases serum TNF α and IL 1β levels [24] . Consistent with our study, it has been shown that in a high cholesterol diet, Vit C reduced the formation of TRAP positive osteo clasts, with decreased RANKL and NF κB expression on the alveolar bone surface [25] . According to our results, Vit C could suppress local osteoclast differentiation formed by favipira vir by decreasing RANKL levels on the alveolar bone surface.

Favipiravir is intended as a drug for oral admin istration with the average doses in humans being reported as 1 600 mg twice a day (followed by 600 mg twice a day) for 10-14 days [26] [27] [28] . However, in animal studies, it is understood that the effective dose is much higher. The effective ness of high doses may be due to the high favipira vir EC 50 pharmacokinetics of the drug [18, 29] . In a clinical study evaluating the favipiravir usage in Ebola infected patients, the dosages used in patients were 6000 mg on day 0, followed by 1200 mg BID for 9 days. The median trough con centrations of favipiravir in serum on days 2 and 4 were 46.1 and 25.9 μg/mL, respectively. In ham sters treated with a high dose (approximately 1400 μg/kg/day), the mean trough concentration is 29.9 μg/mL [30] . However, further studies are needed to determine the most effective and non cytotoxic dose in terms of favipiravir plasma con centrations in patients infected with SARS CoV 2. In a recent study, the effectiveness of favipiravir was researched with (18.75, 37.5 , and 75mg/day TID). The treatment of SARS CoV 2 infected hamsters with different high doses of favipiravir resulted in reduced histopathological damages in the lungs dose dependently, although some toxic ity was noticed, especially with the dose of 75mg/ day TID [29] . The efficacy of administration of favipiravir intraperitoneally or orally twice daily (loading dose of 900 and 1200 mg/kg/day, respec tively, followed by 600 and 1000 mg/kg/day) was evaluated in hamsters highly infected with the virus (2 × 106 TCID 50 ). Regardless of the dose regimen, pulmonary histopathological disorders regressed and no toxicity was observed with favip iravir treatment [31] .

Caspases belong to a proteolytic enzyme fam ily, involved in inflammation and the apoptotic signaling pathway [32] . While caspase 3 has a stimulatory effect in the early phase of RANKL induced osteoclast differentiation, activation of caspase 3 plays an inhibitory role at later stages of RANKL induced osteoclast differentiation [33, 34] . Enhanced caspase 3 levels were detected after antiviral treatments and it was reported that this increase could be used to predict the effec tiveness of antiviral therapy [33, 35] . In an in vitro study performed with favipiravir on human neu ronal progenitor cells, human dermal fibroblasts, human lung adenocarcinoma cells, and Vero cells infected by Asian ZIKV, a significant increase was observed in Bcl 2 mRNA expression levels, while Bax mRNA expression levels were decreased [36] . In the above referenced study, favipiravir seems to have reduced apoptosis in virus infected tissues. In our study, rats were not infected with SARS CoV 2. Although this is seen as a limitation, it was done to fully observe the effects of favipiravir in the periodontium of healthy rats. According to our results, favipiravir provides an increase in caspase 3 immunoexpression in a dose depen dent manner. Vit C has been shown in numerous studies to inhibit oxidative stress and apoptosis [37, 38] . We have also found that caspase 3 levels were diminished in Vit C treated rats. These data suggest that Vit C could attenuate the cellular tox icity developed by favipiravir and therefore may serve as a targeted intervention for apoptosis. BMP 2, released from many cells such as osteoblasts and osteocytes, is an important growth factor involved in bone remodeling and hemosta sis. It regulates osteoblast differentiation by trig gering the release of transcription factors specific to osteoblasts [39] . On the other hand, ALP is an enzyme situated in osteoblasts and involved in mineralization of newly formed bone [40] . In an animal model, it was shown that tenofovir expo sure results in a reduction of ALP levels [41] . Also, it has been reported that enhanced plasma ALP levels following tenofovir administration tes tify to the impairment of bone mineralization [42] . In our study we also observed a decrease in BMP 2 and ALP levels following favipiravir treat ment. These results suggest that favipiravir deteri orates formation of new bones. Vit C plays a crucial role in determining the life cycle as well as proliferation of osteoblasts. Studies have shown that addition of Vit C to osteoblast like cells encourages the initial deposition of the extracellu lar matrix of collagen [8] . Vit C exerts a favorable impact on trabecular bone formation by affecting bone matrix gene release in osteoblasts [8] . It has been reported that Vit C is an essential antioxi dant for bone homeostasis by regulating osteo blastic and osteoclastic activity in osteoporosis models [43] . In addition, Vit C has been described to prevent the reduction in bone mineral volume in postmenopausal women [44] . There is a report that orally applied Vit C supplementation in rats inhibited the expression of osteoclastogenesis related factors such as RANK, RANKL, as well as cathepsin K and induced BMP 2 gene release [45] . Several studies have shown that BMP 2 release is increased [46] and ALP specific genes are induced in osteoblast like cells treated with Vit C [47] . In the present study, Vit C administra tion suppressed the favipiravir induced changes in expression in ALP and BMP 2 and prevented ABL in rat alveolar bones.

In conclusion, our findings showed that two doses of systemic favipiravir administration for 14 days in a rat model increase osteoblast apoptosis and RANKL induced osteoclastogenesis in a dose dependent manner and decrease BMP 2 and ALP immunoreactivity. Concomitant use of Vit C with favipiravir reversed these adverse effects on alveolar bone metabolism. Further investigation of the mechanism of combined action of Favipiravir and Vit C on specific cyto kines that accelerate alveolar bone resorption or formation will be of undeniable value.

Conceptualization, ALA and GTC; methodol ogy, ALA, GTC, ÖÖ, MFD, and YŞ; formal anal ysis, ALA; investigation, ALA, GTC, MFD and YŞ; resources, ÖÖ; writing-original draft, ALA, and ÖÖ; writing-review & editing, ALA, ÖÖ, YŞ and GTC.

who director general s remarks at the media briefing on

China Novel Coronavirus I, Research T (2020) A Novel Coronavirus from Patients with Pneumonia in China

Favip iravir (T 705), a broad spectrum inhibitor of viral RNA polymerase

Favipiravir: Pharmaco kinetics and Concerns About Clinical Trials for 2019 nCoV Infection

Favipiravir and COVID 19: A Simplified Sum mary

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

The Roles and Mechanisms of Actions of Vitamin C in Bone: New Develop ments

Over view of the possible role of vitamin C in manage ment of COVID 19

An Update on Current Therapeutic Drugs Treating COVID 19

BCPT policy for experimental and clinical studies

Broad spectrum antiviral activity of favipiravir (T 705): protection from highly lethal inhalational Rift Valley Fever

The effects of taxifolin on alveolar bone in experimental periodontitis in rats

Effects of a Glyco gen Synthase Kinase 3 Inhibitor Tideglusib on Bone Regeneration With Calvarial Defects

IHC Optical Density Score: A New Practical Method for Quantitative Immunohistochemistry Image Anal ysis

Favipiravir in Therapy of Viral Infections

A review on favipiravir: the properties, function, and usefulness to treat COVID 19

Ebola Virus Infection: Review of the Phar macokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Metabolic bone disease in HIV infection

Physiological and pathophysiological bone turnover-role of the immune system

Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen

Vitamin C mitigates oxidative stress and tumor necrosis fac tor alpha in severe community acquired pneumo nia and LPS induced macrophages

The Protection Potential of Antioxidant Vitamins Against Acute Respiratory Distress Syndrome: a Rat Trial

Vita min C intake inhibits serum lipid peroxidation and osteoclast differentiation on alveolar bone in rats fed on a high cholesterol diet

Early onset favipiravir saves lives

Efficacy of favipiravir in COVID 19 treatment: a multi center random ized study

Favipiravir and its potentials in COVID 19 pandemic: An update

Favipiravir antiviral efficacy against SARS CoV 2 in a hamster model

Favipiravir at high doses has potent antiviral activity in SARS CoV 2 infected hamsters, whereas hydroxychlo roquine lacks activity

Old, new and emerging functions of caspases

Active caspase 3 is required for osteoclast differentiation

An inhibitory role for caspase 3 at the late stage of RANKL induced osteoclast dif ferentiation in RAW264 cells and mouse bone marrow macrophages

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Differ ent Cell Models

Mecha nism of vitamin C inhibition of cell death induced by oxidative stress in glutathione depleted HL 60 cells

Protection of free radical induced cytotox icity by 2 O alpha D glucopyranosyl L ascorbic acid in human dermal fibroblasts

Bone Morphogenetic Protein 2 in Development and Bone Homeostasis

Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma

Tenofovir and bone: age dependent effects in a zebrafish animal model

Adolescent Medicine Trials Network for HIVAI (2019) Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy

Vitamin C intake in relation to bone mineral den sity and risk of hip fracture and osteoporosis: a sys tematic review and meta analysis of observational studies

Vitamin C supplement use and bone min eral density in postmenopausal women

Vita min C Activates Osteoblastogenesis and Inhibits Osteoclastogenesis via Wnt/beta Catenin/ATF4

Ascorbic acid induces either differentiation or apoptosis in MG 63 osteosarcoma lineage

Regulation of alkaline phosphatase by 1,25 dihydroxyvitamin D3 and ascorbic acid in bone derived cells

The authors declare that there is no conflict of interest.